Pulmonary arterial hypertension and systemic sclerosis;Hypertension artérielle pulmonaire associée à la sclérodermie systémique

Presse Medicale

Volumn 35, Issue 12 C2, 2006, Pages 1929-1937

  Launay, David ^a   Humbert, Marc ^b   Hachulla, Eric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE;

CAUSE OF DEATH; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFORMATION; DYSPEPSIA; FACE ERYTHEMA; HEART CATHETERIZATION; HUMAN; IDIOPATHIC DISEASE; LONG TERM EXPOSURE; LUNG TRANSPLANTATION; MEDICAL LITERATURE; NEUROTOXICITY; OXYGEN THERAPY; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SPINAL PAIN; SYMPTOM; SYSTEMIC SCLEROSIS; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

EID: 33845481296     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74927-2     Document Type: Review

References (44)

1. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al. Early detection of pulmonary arterial hypertension in systemic sclerosis. A French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52: 3792-800.
2. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003; 62: 1088-93.
3. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001; 40: 453-9.
4. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2: 20-2.
5. Galiè N, Manes A, Farahni KV, Pelino F, Palazzini M, Negro L et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus. 2005; 14: 713-7.
6. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol. 2006; 33: 269-74
7. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003; 123: 344-50
8. Sanchez O, Humbert M, Sitbon O, Nunes H, Garcia G, Simmonneau G. Hypertension artérielle pulmonaire associée aux connectivites. Rev Med Interne. 2002; 23: 41-54.
9. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43:13S-24S.
10. Mayes M. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum. 2003; 48: 1190-9.
11. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111: 3105-11.
12. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003; 62: 97-9
13. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003; 48: 516-22.
14. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004; 43(12 Suppl S): 5S-12S
15. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary Arterial Hypertension in France: Results from a National Registry. Am J Respir Crit Care Med. 2006; 173: 1023-30.
16. Hachulla E. Traitement de l'hypertension artérielle pulmonaire associée à la sclérodermie systémique. Rev Med Interne. 2004; 25: 195-200.
17. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis. 2004; 63: 1009-14.
18. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351: 1425-36.
19. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006; 130: 182-9.
20. Provencher S, Herve P, Jaïs X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of b-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006; 130: 120-6.
21. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327: 76-81.
22. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000; 132: 425-34.
23. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40: 780-8.
24. Faber CN, Yousem SA, Dauber JH, Griffith BP, Hardesty RL, Parasis IL. Pulmonary capillary hemangiomatosis. A report of three cases and a review of the literature. Am Rev Respir Dis. 1989; 140: 808-13.
25. Launay D, Hachulla E, Hatron PY, Goullard L, Onimus T, Robin S et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol. 2001; 28: 2252-6.
26. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ et al. Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease Chest. 2004; 126: 420.
27. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A et al. Safety and Efficacy of IV Treprostinil for Pulmonary Arterial Hypertension: A Prospective, Multicenter, Open-Label, 12-Week Trial. Chest. 2006; 129: 683-8.
28. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896-903.
29. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005; 25: 244-9.
30. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart. 2006; 92: 926-32.
31. Korn JH, Mayes M, Matucci CM, Rainisio M, Pope J, Hachulla E et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004; 50: 3985-93.
32. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169: 441-7
33. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353: 2148-57.
34. Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest. 2003; 123:1293-5.
35. Ghofrani A, Rose F, Schermuly R, Olschewski H, Wiedermann R, Kreckel A et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 42:158-64.
36. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J. 2003; 22: 330-4.
37. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005; 353: 1412-3.
38. Schermuly RT, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115: 2811-21.
39. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005; 115: 2691-4.
40. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest. 2004; 126: 1330-6.
41. Schachna L, Braunstein NA, Dauber JH, Wigley FM, Medsger TA, White B et al. Lung transplantation for systemic sclerosis compared with idiopathic pulmonary fibrosis: increased early mortality but comparable survival at one year. Arthritis Rheum. 2002; 46(suppl): S382.
42. Galiè N, Seeger W, Naeje R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43(12 Suppl S): 81S-88S.
43. Sitbon O, Humbert M, Simonneau G; Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine.Les traitements de l'hypertension artérielle pulmonaire à l'heure de la T2A. Recommandations du groupe de travail "Maladies vasculaires pulmonaires" de la Société de pneumologie de langue française. Presse Med. 2005; 34: 1456-64.
44. Launay D, Rémy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M et al. Evolution of high-resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006; 33: 1789-801.